Finolex Industries Ltd. - Research Center
500940 FINPIPE Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 4,317.43 | 4,397.05 | 4,647.32 | 3,462.82 | 2,985.98 |
| Operating profit | 584.85 | 292.54 | 1,023.74 | 989.31 | 448.07 |
| Interest | 36.45 | 27.23 | 14.09 | 7.27 | 11.91 |
| Gross profit | 729.51 | 386.69 | 1,092.81 | 1,054.52 | 467.00 |
| EPS (Rs) | 7.36 | 3.83 | 16.98 | 11.73 | 5.22 |
Annual
results in details
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 181.11 | 121.38 | 83.16 | 72.48 | 30.84 |
| Stock adjustment | -40.00 | 149.56 | 32.60 | -21.48 | -108.88 |
| Raw material | 2,744.92 | 2,903.15 | 2,801.75 | 1,940.24 | 2,037.71 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 211.39 | 189.67 | 190.84 | 166.80 | 145.55 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 816.27 | 862.13 | 598.39 | 387.95 | 463.53 |
| Provisions made | - | - | - | - | - |
| Depreciation | 116.02 | 89.20 | 83.40 | 77.72 | 73.81 |
| Taxation | 158.19 | 60.90 | 332.00 | 248.78 | 68.99 |
| Net profit / loss | 455.30 | 236.59 | 1,053.47 | 728.02 | 324.20 |
| Extra ordinary item | - | - | 376.06 | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 123.67 | 123.67 | 124.10 | 124.10 | 124.10 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 13.55 | 6.65 | 22.03 | 28.57 | 15.01 |
| GPM (%) | 16.22 | 8.56 | 23.10 | 29.83 | 15.48 |
| NPM (%) | 10.12 | 5.24 | 22.27 | 20.59 | 10.75 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis